A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study.

Monish Ahluwalia,Ambika Parmar,Eric Xueyu Chen,Derek J. Jonker,Jonathan M. Loree,Christopher J. OCallaghan,Nicole Mittmann,Matthew C. Cheung,Harriet Feilotter,Jose Gerard Monzon,Dawn Marie Ng,Tarek Elfiki,Nazik Hammad,Frédéric Lemay,Anouk Tremblay,Stacey Hubay,John Lenehan,Muhammad Salim,Dongsheng Tu,Kelvin K. W. Chan

A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study.

2021

e15581Background: The randomized phase II CCTG CO.26 clinical trial investigated the use of combined durvalumab and tremelimumab vs. best supportive care (BSC) for patients with mCRC and suggested ...

Keywords:

Medicine
Internal medicine
Oncology
Colorectal cancer
in patient
Tremelimumab
Cost–utility analysis
Clinical trial
Refractory
Cancer
Durvalumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations